Esperion Therapeutics (NASDAQ:ESPR) Cut to Underperform at Bank of America

Bank of America lowered shares of Esperion Therapeutics (NASDAQ:ESPRFree Report) from a neutral rating to an underperform rating in a report released on Thursday, MarketBeat reports. They currently have $2.50 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $2.90.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reissued a buy rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, May 21st. StockNews.com cut shares of Esperion Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, May 17th. Finally, Needham & Company LLC restated a buy rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of $8.83.

View Our Latest Stock Analysis on Esperion Therapeutics

Esperion Therapeutics Trading Down 3.5 %

Shares of ESPR stock opened at $2.21 on Thursday. The firm’s fifty day moving average price is $2.28 and its two-hundred day moving average price is $2.38. Esperion Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.40. The firm has a market capitalization of $418.71 million, a P/E ratio of -2.23 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.42. The company had revenue of $137.74 million during the quarter, compared to analyst estimates of $53.11 million. As a group, equities research analysts forecast that Esperion Therapeutics will post -0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Spire Wealth Management lifted its stake in shares of Esperion Therapeutics by 69.2% during the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 7,267 shares during the last quarter. Private Portfolio Partners LLC bought a new stake in shares of Esperion Therapeutics during the fourth quarter worth approximately $30,000. Herbst Group LLC acquired a new position in shares of Esperion Therapeutics in the first quarter valued at approximately $28,000. Summit Financial LLC increased its stake in shares of Esperion Therapeutics by 66.8% during the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 10,355 shares during the period. Finally, PSI Advisors LLC lifted its holdings in Esperion Therapeutics by 161.5% during the 4th quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 10,500 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Featured Articles

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.